See more : Aluminum Corporation of China Limited (ACHHY) Income Statement Analysis – Financial Results
Complete financial analysis of AVROBIO, Inc. (AVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVROBIO, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Heiwa Paper Co.,Ltd. (9929.T) Income Statement Analysis – Financial Results
- GTI Holdings Limited (3344.HK) Income Statement Analysis – Financial Results
- VHM Limited (VHM.AX) Income Statement Analysis – Financial Results
- BRP Inc. (DOOO) Income Statement Analysis – Financial Results
- Captor Therapeutics Spolka Akcyjna (CTX.WA) Income Statement Analysis – Financial Results
AVROBIO, Inc. (AVRO)
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 47.08M | 72.19M | 83.11M | 87.24M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 22.69M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Selling & Marketing | 23.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.97M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Other Expenses | 0.00 | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -19.00K | -6.00K |
| Operating Expenses | 71.05M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Cost & Expenses | 71.67M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 299.00 | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 2.42M | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00K | 1.44M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 39.00K |
| EBITDA | -71.05M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.04M | -4.59M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.67M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | 12.53M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 157.00K | -1.40M | -1.21M | -850.00K | -118.00K | 243.00K | -6.00K |
| Net Income | 12.16M | -106.05M | -117.73M | -118.51M | -72.12M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| EPS Diluted | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| Weighted Avg Shares Out | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
| Weighted Avg Shares Out (Dil) | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen...
AVROBIO to Present at the ICR Conference 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR...
Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts
AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipeline of six gene-therapeutics covering Fabry's disease (AVR-RD-01), Gaucher Type 1 (AVR-RD-02), Cystinosis (AVR-RD-04), Hunter syndrome (AVR-RD-05), Gaucher...
AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise.
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of...
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds...
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry...
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up...
Online Investment Platform Offering Shares Of 1937 Heisman Trophy, Other Sports Memorabilia
The 1937 Heisman Trophy is being offered via Rally Rd., an online investment platform. Any U.S. adult with a Social Security number and bank account can buy shares for $46 apiece.
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
Source: https://incomestatements.info
Category: Stock Reports